Neumora Therapeutics Inc. (NASDAQ: NMRA) on Monday, soared 0.58% from the previous trading day, before settling in for the closing price of $15.51. Within the past 52 weeks, NMRA’s price has moved between $8.33 and $21.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 59.37%. With a float of $54.90 million, this company’s outstanding shares have now reached $158.83 million.
Let’s determine the extent of company efficiency that accounts for 124 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc. (NMRA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Neumora Therapeutics Inc. is 65.69%, while institutional ownership is 27.62%. The most recent insider transaction that took place on Oct 10 ’24, was worth 124,603. In this transaction Head of R&D of this company sold 8,260 shares at a rate of $15.09, taking the stock ownership to the 314,706 shares. Before that another transaction happened on Oct 09 ’24, when Company’s Head of R&D sold 5,563 for $15.01, making the entire transaction worth $83,507. This insider now owns 322,966 shares in total.
Neumora Therapeutics Inc. (NMRA) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.14 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.36) by -0.78. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.37% per share during the next fiscal year.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Trading Performance Indicators
Neumora Therapeutics Inc. (NMRA) is currently performing well based on its current performance indicators. A quick ratio of 17.22 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.56 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc. (NMRA)
Looking closely at Neumora Therapeutics Inc. (NASDAQ: NMRA), its last 5-days average volume was 1.34 million, which is a jump from its year-to-date volume of 0.66 million. As of the previous 9 days, the stock’s Stochastic %D was 83.37%. Additionally, its Average True Range was 0.91.
During the past 100 days, Neumora Therapeutics Inc.’s (NMRA) raw stochastic average was set at 92.85%, which indicates a significant increase from 86.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.02% in the past 14 days, which was lower than the 54.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.34, while its 200-day Moving Average is $12.82. However, in the short run, Neumora Therapeutics Inc.’s stock first resistance to watch stands at $16.13. Second resistance stands at $16.65. The third major resistance level sits at $17.15. If the price goes on to break the first support level at $15.11, it is likely to go to the next support level at $14.61. Should the price break the second support level, the third support level stands at $14.09.
Neumora Therapeutics Inc. (NASDAQ: NMRA) Key Stats
Market capitalization of the company is 2.50 billion based on 159,524K outstanding shares. Right now, sales total 0 K and income totals -235,930 K. The company made 0 K in profit during its latest quarter, and -58,700 K in sales during its previous quarter.
